2022-23 Highlights
- Launch of UZEDY™, first commercial product based on BEPO® technology in May 2023 (post-closing)
- Successful financing strategy: European Investment Bank loan (November 2022) and fundraising (May 2023, post-closing)
- Products for schizophrenia and post-operative pain based on BEPO, entered Phase 3 clinical trials, and the rest of the pipeline has progressed with three new programs expected to enter Phase 1 clinical trials in 2024
Consolidated FY 2023 financials
- Income from ordinary activities: € 13.7 million, +64% vs previous year
- Operating expenses: € 37.7 million, +17% vs previous year, 74% of the expenses are devoted to R&D
- Cash consumption from operating activities: € 21.2 million, -1% vs previous year